Participated · Seed · Jun 2022

Wonder Sciences launched Wondermed, an at‑home ketamine‑assisted treatment that pairs low‑dose, self‑administered ketamine lozenges with a structured telehealth protocol integrating psychiatry and psychology. Patients complete an eligibility survey and clinician telehealth visit, then follow a personalized weekly session plan supported by remote check‑ins, soundscapes, journaling prompts and integration resources. Wondermed charges an introductory rate of $249 per month, which includes four lozenges for self‑led sessions, clinician support, and a personalized dashboard. The company reports that 92 percent of patients experience a decrease in anxiety following their first session. Wonder Sciences is accepting patients in California, New York, Florida and Texas, plans near‑term expansion into Illinois, Arizona and Connecticut, and aims to be available in 19 states by year‑end. The company is also developing a database of partner mental health professionals to provide recommendations to patients.

Participated · Series A · Feb 2022

Willow Industries develops WillowPure, a patented, organic ozone-based post-harvest microbial decontamination technology for cannabis. The technology is scientifically proven to reduce or eliminate contaminants such as yeast, mold and bacteria while protecting the plant's medicinal properties. Willow focuses on providing cultivators with a kill-step solution to deliver clean, high-quality products to patients and consumers. Its WillowPure system is currently deployed in 26 U.S. states. The company has begun international expansion into Canada and Australia. Willow intends to use the new funds to accelerate its international growth. Willow Industries builds the patent-pending WillowPure ozone systems to remove microbial contaminants from harvested cannabis while preserving terpenes, potency, color and taste. The technology uses industry-recognized USDA/EPA approved ozone gas and is described as environmentally friendly, non-toxic, and scalable. Willow has deployed WillowPure in three volume-scaled, mobile units to serve boutique cultivators through large multi-state operators and currently operates in nine states. The company says its solution has saved cultivators over $50M in flower failure. Willow positions its product around consumer safety and helping cultivators sell clean, high-quality cannabis, and expects to scale and expand alongside the legal cannabis industry domestically and internationally.

Participated · Series C · Nov 2021

Chicago-based Fyllo, led by founder and CEO Chad Bronstein, delivers the Compliance Cloud, a suite of software and services that simplifies regulatory management for companies operating in tightly controlled sectors like cannabis. Its offering combines compliance monitoring, data services and marketing tools, and is complemented by the Fyllo Data Marketplace, which lets mainstream advertisers target cannabis and CBD consumers. The company is expanding its capabilities through M&A, including the February 2021 acquisition of retail and marketing platform DataOwl. Fyllo plans to continue strategic acquisitions and aggressive hiring to bolster its technology stack. Year-to-date in 2021 the business has grown revenue more than 100% and expanded headcount by roughly 275%, adding executives from firms such as Twitter and Salesforce. These metrics underscore rising demand for compliance-first SaaS in regulated markets, positioning Fyllo for continued growth.

Participated · Seed · Mar 2021

Rev Ventures operates a portfolio of digital companies with a wholly-owned flagship, RevOffers, which connects brands with publishers in Health, Pet and Home verticals. RevOffers specializes in performance and affiliate marketing in the CBD space and has generated tens of millions of dollars a year in e-commerce sales for leading brands. Its core product is a proprietary Attribution Engine powered by an Identity Graph that processes thousands of data points across the customer journey to attribute credit to publishers. The Attribution Engine aims to deliver higher match rates and consistent accuracy for advertisers and publishers, and next-generation development will focus on tools for advertisers to manage performance partnerships across the digital landscape. The company was bootstrapped for three years under co-founders Jason Brett (CEO) and Matthew Stein (CRO) before this financing. Rev Ventures plans to use new capital to grow its management team, expand marketing efforts, and further develop the Attribution Engine.

Participated · Equity · Sep 2019

Front Range Biosciences specializes in next-generation plant breeding, plant tissue culture, and cannabis seed development to improve the reliability and quality of industrial hemp and medical cannabis genetics. The company runs a Clean Stock program that supplies disease- and pathogen-free plants and seeds backed by data-driven breeding solutions. FRB operates facilities in Colorado, California and Wisconsin and maintains a partnership with the Center for Research in Agricultural Genomics in Barcelona, Spain, giving it global reach. Founded in 2015 and headquartered in Lafayette, Colorado, the company positions itself as a market-leading R&D program in hemp and cannabis genetics. FRB is currently raising a $30M Series B financing round and has attracted investment from KEY Investment Partners, which will act as a strategic partner. KEY founding partner Pete Karabas is joining Front Range Biosciences' board as a board observer. Front Range Biosciences is a Lafayette, Colorado–based agricultural biotech that provides technology for breeding and producing new plant varieties and seeds in hemp, coffee and regulated cannabis. The company raised $8.5M in funding to support continued expansion of its hemp and cannabis portfolio. FRB plans to expand hemp seed production both nationally and globally and scale its young plant program, with production capabilities expected to multiply in 2020. Led by CEO and Co‑Founder Jon Vaught, the company has operated for a little more than three years. During that time FRB built over 160,000 square feet of facilities across Colorado, California and Wisconsin, acquired a cannabis genomics team and shipped millions of plants to farmers and growers nationwide. The new funds are intended to accelerate those production and portfolio expansion efforts. Front Range Biosciences develops Clean Stock® plant material using tissue culture, a sterile propagation technique, to address disease, inefficiency, inconsistency and scale for high-value crops. Its core product is sterile, duplicated baby plants on a defined nutrient medium for crops such as hemp, cannabis and coffee. The company supplies Clean Stock to growers and has partnerships to expand production, including with Frinj Coffee for coffee cuttings and Faith and Family Farms for cannabis in California. Led by CEO and co-founder Dr. Jonathan Vaught, Front Range is expanding Clean Stock production into California and taking orders for late 2018. It plans to use new funding to accelerate its Clean Stock program across Colorado, California and Canada, pursue IP development, and resource its varietal development program for hemp and cannabis. Front Range Biosciences specializes in tissue culture propagation of high-value crops, aiming to resolve cultivators' operational problems such as disease, inefficiency, inconsistency and limited scale. The company runs a varietal improvement program that leverages sequencing technology to map cannabis genetics and develop commercially relevant traits, including disease resistance, oil and resin yield, and desirable cannabinoid profiles. Front Range is led by CEO and co-founder Dr. Jon Vaught and COO and co-founder Nick Hofmeister. The company intends to use recent funding to scale its processes and expand into California and other legal cannabis states in the U.S. Its core product and R&D focus combine propagation services with genetic improvement to deliver more reliable, higher-yielding plant varieties for cultivators. Front Range Biosciences offers industrial-scale tissue culture propagation and an advanced breeding platform aimed at improving cannabis clone consistency and commercial traits. Its flagship product is tissue culture propagation for scalable, consistent clone production. The company also develops breeding tools to identify and enhance commercially relevant traits. Front Range will use new funding to build out its team and expand its tissue culture offering to improve efficiency and consistency for clone production. The company participated in the CanopyBoulder accelerator program for cannabis startups last year. It recently closed a $1.5 million seed round to support these efforts.